Daily Brief China: Zhongji InnoLight, Get Nice, Immvira Bioscience and more

• Zhongji InnoLight is a leading global provider of optical interconnect solutions, offering transceivers that convert electrical and optical signals for data transmission.
• As the world’s largest provider of optical interconnect solutions by revenue, we were first to introduce 400G, 800G, and 1.6T transceivers.
• For the three months ended March 31, 2026, revenue was 19,496,398 thousand, with an adjusted net profit margin of 33.9%.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Get Nice (64 HK)/GNH has disclosed a scheme offer from Mr Hung Hon Man (founder and Chairman) at HK$4.00 (scheme consideration of HK$2.00 + special dividend of HK$2.00).
• While the offer represents a five-year high, it is light, implying a P/B multiple at a discount to precedent transactions and peer multiples. 
• However, the scheme vote is low-risk, as no disinterested shareholder holds a blocking stake. Unless an activist(s) takes an interest by building a blocking stake, this is a done deal.

• Immvira Bioscience Inc. is a clinical-stage biotechnology company focused on novel oncolytic immunotherapies and engineered exosome therapies, aiming to be a global leader in bladder cancer treatment.
• Immvira, incorporated in 2015, has a pipeline of two oncolytic immunotherapy candidates and five engineered exosome assets. MVR-T3011 received FDA Fast Track Designation for HNSCC in March 2024.
• The company reported a loss of RMB(518,861) for 2025, with net current liabilities of RMB(2,390,634) as of May 31, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.